| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H32N4O3S |
| Molecular Weight | 504.644 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCS(=O)(=O)C1=CC(=CC=C1)C2=CC(C(=O)NC3CCN(C)CC3)=C(C)C4=C2C5=CC(C)=CN=C5N4
InChI
InChIKey=WKDACQVEJIVHMZ-UHFFFAOYSA-N
InChI=1S/C28H32N4O3S/c1-5-36(34,35)21-8-6-7-19(14-21)23-15-22(28(33)30-20-9-11-32(4)12-10-20)18(3)26-25(23)24-13-17(2)16-29-27(24)31-26/h6-8,13-16,20H,5,9-12H2,1-4H3,(H,29,31)(H,30,33)
| Molecular Formula | C28H32N4O3S |
| Molecular Weight | 504.644 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Millennium (a wholly-owned subsidiary of Takeda) was developing TAK- 901 for the treatment of cancer. TAK-901 is an inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. TAK-901 is in phase I clinical trials by Millennium Pharmaceuticals for the treatment of advanced hematological malignancies. TAK-901 had been in phase I clinical trials for solid tumors. However, this study was discontinued.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Rats:Tumor regressions were observed at the highest dose
levels of TAK-901 in several xenograft models, including
95% at 45 mg/kg twice daily in (nude rat) ovarian A2780 model
Route of Administration:
Intravenous
